ATB-320

ATB-320 is an **antisense oligonucleotide (ASO)** drug developed by Autotelic Bio. It is an investigational RNA-based therapeutic designed for oncology indications, with preclinical and early clinical efforts focused on a range of **solid tumors**, including bile duct neoplasms, melanoma, pancreatic cancer, and triple negative breast cancer. The drug is described as having a **dual action mechanism** that targets both the tumor microenvironment (TME) and angiogenesis, suggesting it interferes with the supportive milieu around tumors and their blood supply to inhibit tumor growth. As of June 2025, ATB-320 is in **Phase 1 clinical trials** to evaluate its safety and tolerability in patients with progressive or metastatic solid tumors[1][2][7][9]. The developer and primary sponsor is Autotelic Bio.